Susceptibility profile of clinical isolates of non-Cryptococcus neoformans/non-Cryptococcus gattii Cryptococcus species and literature review

Medical Mycology

Volumn 48, Issue 1, 2010, Pages 90-96

  Bernal Martinez, Leticia ^a   Gomez Lopez, Alicia ^a   Castelli, Maria V ^a   Mesa Arango, Ana C ^a,b   Zaragoza, Oscar ^a   Rodriguez Tudela, Juan L ^a   Cuenca Estrella, Manuel ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Amphotericin B; Basidiomycetous; Echinocandins; Emerging pathogens

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCUS; CRYPTOCOCCUS ALBIDUS; CRYPTOCOCCUS CURVATUS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS HUMICOLA; CRYPTOCOCCUS LAURENTII; CRYPTOCOCCUS LUTEOLUS; CRYPTOCOCCUS NEOFORMANS; CRYPTOCOCCUS UNIGUTTULATUS; FUNGAL STRAIN; IN VITRO STUDY; NONHUMAN; CRYPTOCOCCOSIS; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

CRYPTOCOCCUS ALBIDUS; CRYPTOCOCCUS CURVATUS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS HUMICOLA; CRYPTOCOCCUS LAURENTII; CRYPTOCOCCUS LUTEOLUS; FILOBASIDIUM UNIGUTTULATUM;

ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 74949114978     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780902756073     Document Type: Article

References (31)

1. Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Nonneoformans cryptococcal infections: a systematic review. Infection 2007; 35: 51-58.
2. Kielstein P, Hotzel H, Schmalreck A, Khaschabi D, Glawischnig W. Occurrence of Cryptococcus spp. in excreta of pigeons and pet birds. Mycoses 2000; 43: 7-15.
3. Mattsson R, Haemig PD, Olsen B. Feral pigeons as carriers of Cryptococcus laurentii, Cryptococcus uniguttulatus and Debaryomyces hansenii. Med Mycol 1999; 37: 367-369.
4. Garelick JM, Khodabakhsh AJ, Lopez Y, Bamji M, Lister M. Scleral ulceration caused by Cryptococcus albidus in a patient with acquired immune deficiency syndrome. Cornea 2004; 23: 730-731.
5. Narayan S, Batta K, Colloby P, Tan CY. Cutaneous cryptococcus infection due to C. albidus associated with Sezary syndrome. Br J Dermatol 2000; 143: 632-634.
6. Ramchandren R, Gladstone DE. Cryptococcus albidus infection in a patient undergoing autologous progenitor cell transplant. Transplantation 2004; 77: 956.
7. Wells GM, Gajjar A, Pearson TA, Hale KL, Shenep JL. Brief report. Pulmonary cryptosporidiosis and Cryptococcus albidus fungemia in a child with acute lymphocytic leukemia. Med Pediatr Oncol 1998; 31: 544-546.
8. Burnik C, Altintas ND, Ozkaya G, et al. Acute respiratory distress syndrome due to Cryptococcus albidus pneumonia: case report and review of the literature. Med Mycol 2007; 45: 469-473.
9. Gluck JL, Myers JP, Pass LM. Cryptococcemia due to Cryptococcus albidus. South Med J 1987; 80: 511-513.
10. Vlchkova-Lashkoska M, Kamberova S, Starova A, et al. Cutaneous Cryptococcus laurentii infection in a human immunodeficiency virusnegative subject. J Eur Acad Dermatol Venereol 2004; 18: 99-100.
11. Cheng MF, Chiou CC, Liu YC, Wang HZ, Hsieh KS. Cryptococcus laurentii fungemia in a premature neonate. J Clin Microbiol 2001; 39: 1608-1611.
12. Averbuch D, Boekhoutt T, Falk R, et al. Fungemia in a cancer patient caused by fl uconazole-resistant Cryptococcus laurentii. Med Mycol 2002; 40: 479-484.
13. Bauters TG, Swinne D, Boekhout T, Noens L, Nelis HJ. Repeated isolation of Cryptococcus laurentii from the oropharynx of an immunocompromised patient. Mycopathologia. 2002; 153: 133-135.
14. Shankar EM, Kumarasamy N, Bella D, et al. Pneumonia and pleural effusion due to Cryptococcus laurentii in a clinically proven case of AIDS. Can Respir J 2006; 13: 275-278.
15. Manzano-Gayosso P, Hernandez-Hernandez F, Mendez-Tovar LJ, et al. Onychomycosis incidence in type 2 diabetes mellitus patients. Mycopathologia 2008; 166: 41-45.
16. Pedroso RS, Ferreira JC, Candido RC. In vitro susceptibility to antifungal agents of environmental Cryptococcus spp. isolated in the city of Ribeirao Preto, Sao Paulo, Brazil. Mem Inst Oswaldo Cruz. 2006; 101: 239-243.
17. Rogowska-Szadkowska D, Wiercinska-Drapalo A, Borzuchowska A, Prokopowicz D. [ Candida humicola infection of the central nervous system in an HIV-infected patient: a case report]. Przegl Epidemiol 1997; 51: 465-469.
18. Alvarez Gasca MA, Arguero LB, Pliego CA, Garcia TS. Fungal agents isolated from cancer patients. Rev Latinoam Microbiol 1998; 40: 15-24.
19. Shinde SM, Vanarse KS, Pandit AN. Systemic humicolus cryptococcosis. Indian Pediatr 2004; 41: 1162-1164.
20. Testore GP, Falco F, Sarrecchia C, et al. Two-year surveillance on fl uconazole susceptibility of Candida spp. isolates in a general and university hospital in Rome. Diagn Microbiol Infect Dis. 2001; 41: 23-27.
21. Dromer F, Moulignier A, Dupont B, et al. Myeloradiculitis due to Cryptococcus curvatus in AIDS. AIDS 1995; 9: 395-396.
22. Kurtzman CP, Fell JW. The Yeasts: A Taxonomic Study. 4th ed, Amsterdam: Elsevier, 1998.
23. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, et al. EUCAST DefInitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Inf 2008; 14: 398-405.
24. Rodriguez-Tudela JL, Martin-Diez F, et al. Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: a comparison of the NCCLS standard M27A medium, buffered yeast nitrogen base, and RPMI-2% glucose. Antimicrob Agents Chemother 2000; 44: 400-404.
25. Garcia-Martos P, Noval JF, Garcia-Tapia A, et al. [Susceptibility to antifungal agents of Cryptococcus species of clinical interest]. Med Clin (Barc) 2002; 119: 211-213.
26. Kordossis T, Avlami A, Velegraki A, et al. First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients. Med Mycol 1998; 36: 335-339.
27. Quindos G, Ruesga MT, Martin-Mazuelos E, et al. In-vitro activity of 5-fluorocytosine against 1,021 Spanish clinical isolates of Candida and other medically important yeasts. Rev Iberoam Micol 2004; 21: 63-69.
28. Serena C, Pastor FJ, Ortoneda M, et al. In vitro antifungal susceptibilities of uncommon basidiomycetous yeasts. Antimicrob Agents Chemother 2004; 48: 2724-2726.
29. Ryder NS, Wagner S, Leitner I. In vitro activities of terbinafIne against cutaneous isolates of Candida albicans and other pathogenic yeasts. Antimicrob Agents Chemother 1998; 42: 1057-1061.
30. Shimokawa O, Niimi M, Kikuchi K, et al. Relationship between MIC and minimum sterol 14 -demethylation-inhibitory concentration as a factor in evaluating activities of azoles against various fungal species. J Clin Microbiol 2005; 43: 5547-5549.
31. Feldmesser M, Kress Y, Mednick A, Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis 2000; 182: 1791-1795.